Navigation Links
Bone Therapy May Not Always Need Monitoring
Date:6/24/2009

In older women, annual measurements are unnecessary, study finds

WEDNESDAY, June 24 (HealthDay News) -- Monitoring bone density in older women after they've started taking drugs to prevent osteoporosis is unnecessary and could be potentially misleading, researchers say.

In the study, Australian researchers analyzed data from a large randomized trial that compared the effects of the drug alendronate (a widely used bisphosphonate) in more than 6,000 postmenopausal women with low bone mineral density, which is a risk factor for fractures.

The women's bone density was measured at the start of the study and again one, two and three years later. After three years of treatment, 97.5 percent of the women who took the drug showed at least a modest increase in bone density, and there was little variation in the treatment effect between individuals, the researchers found.

The findings, which appear online June 24 in BMJ, suggest that monitoring a person's response during the first three years of the treatment is unnecessary and, because of the potential to mislead, should not be done, concluded the researchers, from the School of Public Health at the University of Sydney.

The results support the case against routine monitoring during the early years of treatment, according to an accompanying editorial by Juliet Compston, professor of bone medicine at the University of Cambridge, in England. She said that when changes in bone mineral density are used to monitor treatment, people may be given inappropriate advice.

"Routine monitoring of bone mineral density during the first few years of antiresorptive treatment cannot be justified because it may mislead patients, lead to inappropriate management decisions and waste scarce health care resources," she concluded.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases offers tips on bone health for life.



-- Robert Preidt



SOURCE: BMJ, news release, June 23, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Dynatronics Begins Shipping New V-Force Vibration Therapy Units
2. Biomarkers predict brain tumors response to therapy
3. Determining Who Will Respond to Brain Tumor Therapy
4. Promising Therapy for Prostate Cancer
5. AthletiCo Opens 52nd Physical Therapy Center in South Elgin
6. Platelet Rich Plasma Therapy (PRP) Accelerates Healing of Joint Injuries, Osteoarthritis Pain
7. US Brachytherapy Market to Reach $1.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
8. Video: New Biological Therapy Ilaris(R) Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
9. Varians RapidArc Radiotherapy Technology Enables Pioneering Cancer Treatments at Top Dutch Oncology Center
10. Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital
11. Spinal Decompression Therapy Offers Hope for Back Pain
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Bone Therapy May Not Always Need Monitoring 
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: